FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4211054795> ?p ?o ?g. }

• W4211054795 abstract "In recent years, the new third-generation ultrathin bioresorbable-polymer sirolimus-eluting stent (BP-SES), characterized by some of the thinnest struts among commercially available devices (60-80 μm) and an amorphous silicon carbide coating, has been introduced for the treatment of coronary artery disease (CAD). The present study aimed to assess different clinical outcomes and safety of this drug-eluting stent in male and female patients in a real-world setting.The present study is a retrospective analysis including all patients treated with BP-SES between January 2017 and December 2019 at a single high-volume center. Follow-up data, including stress test results and clinical setting, were collected during outpatient visits or by telephone contact. Patients symptomatic for angina or with a positive stress test were addressed to CT scan/coronary angiogram. The main study outcome was target lesion failure (TLF), defined as a composite of cardiovascular death, target vessel myocardial infarction, or target lesion revascularization.Overall, 66 (15.9%) female and 349 (84.1%) male patients were included; women were older (median age 70 vs. 66, P = 0.003) and with a lower body mass index (BMI) (25.0 vs. 26.1, P = 0.010) compared to men, with no other relevant differences in baseline characteristics. Indication for percutaneous coronary intervention (PCI) was acute coronary syndrome in 86 (20.7%) of the cases, with no significant differences between male and female patients. A total of 558 lesions were treated with BP-SES stents, 90 in women and 468 in men (1.36 vs. 1.34 lesions per patient, P = 0.83); cumulative stent length (33.6 vs. 38.4 mm, P = 0.078), and mean stent diameter (2.92 vs. 3.0 mm, P = 0.39) did not differ in women compared to men. Technical and clinical successes were achieved in all patients. Stent thrombosis (ST) occurred in 2 (0.5%) patients, both men. TLF occurred in 10 (2.9%) men and 2 (3.0%) women after a median follow-up of 402 days, without significant differences at log-rank analysis (2.34 events per 100 patient-years in men, 2.53 in women; P = 0.80).Ultrathin struts BP-SES showed to be a safe and effective option for the treatment of CAD in both women and men, with a very low ST rate and favorable long-term outcomes." @default.
• W4211054795 created "2022-02-13" @default.
• W4211054795 creator A5004606355 @default.
• W4211054795 creator A5015188296 @default.
• W4211054795 creator A5036236043 @default.
• W4211054795 creator A5036797392 @default.
• W4211054795 creator A5054473346 @default.
• W4211054795 creator A5080369703 @default.
• W4211054795 creator A5083236244 @default.
• W4211054795 creator A5087838868 @default.
• W4211054795 creator A5090353733 @default.
• W4211054795 date "2022-02-11" @default.
• W4211054795 modified "2023-09-26" @default.
• W4211054795 title "Gender-Associated Outcomes Following Percutaneous Coronary Intervention With a Third-Generation, Ultrathin-Strut Drug-Eluting Stent: A Real-World, Single-Center Experience" @default.
• W4211054795 cites W1988640627 @default.
• W4211054795 cites W2048959087 @default.
• W4211054795 cites W2106707686 @default.
• W4211054795 cites W2124385743 @default.
• W4211054795 cites W2166967848 @default.
• W4211054795 cites W2168008786 @default.
• W4211054795 cites W2325109603 @default.
• W4211054795 cites W2410733054 @default.
• W4211054795 cites W2594531272 @default.
• W4211054795 cites W2747702104 @default.
• W4211054795 cites W2754054868 @default.
• W4211054795 cites W2765956633 @default.
• W4211054795 cites W2800815486 @default.
• W4211054795 cites W2884927836 @default.
• W4211054795 cites W2888543854 @default.
• W4211054795 cites W2890691602 @default.
• W4211054795 cites W2892287671 @default.
• W4211054795 cites W2942470819 @default.
• W4211054795 cites W2968818608 @default.
• W4211054795 cites W3011371150 @default.
• W4211054795 cites W3017818538 @default.
• W4211054795 cites W3036060213 @default.
• W4211054795 cites W3126847189 @default.
• W4211054795 cites W3139301516 @default.
• W4211054795 cites W3157885294 @default.
• W4211054795 cites W3162195278 @default.
• W4211054795 cites W4230914943 @default.
• W4211054795 cites W4238277289 @default.
• W4211054795 doi "https://doi.org/10.3389/fcvm.2021.796604" @default.
• W4211054795 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35224025" @default.
• W4211054795 hasPublicationYear "2022" @default.
• W4211054795 type Work @default.
• W4211054795 citedByCount "0" @default.
• W4211054795 crossrefType "journal-article" @default.
• W4211054795 hasAuthorship W4211054795A5004606355 @default.
• W4211054795 hasAuthorship W4211054795A5015188296 @default.
• W4211054795 hasAuthorship W4211054795A5036236043 @default.
• W4211054795 hasAuthorship W4211054795A5036797392 @default.
• W4211054795 hasAuthorship W4211054795A5054473346 @default.
• W4211054795 hasAuthorship W4211054795A5080369703 @default.
• W4211054795 hasAuthorship W4211054795A5083236244 @default.
• W4211054795 hasAuthorship W4211054795A5087838868 @default.
• W4211054795 hasAuthorship W4211054795A5090353733 @default.
• W4211054795 hasBestOaLocation W42110547951 @default.
• W4211054795 hasConcept C126322002 @default.
• W4211054795 hasConcept C141071460 @default.
• W4211054795 hasConcept C164705383 @default.
• W4211054795 hasConcept C2777546689 @default.
• W4211054795 hasConcept C2777698277 @default.
• W4211054795 hasConcept C2778213512 @default.
• W4211054795 hasConcept C2778425758 @default.
• W4211054795 hasConcept C2778583881 @default.
• W4211054795 hasConcept C2780400711 @default.
• W4211054795 hasConcept C45393284 @default.
• W4211054795 hasConcept C500558357 @default.
• W4211054795 hasConcept C71924100 @default.
• W4211054795 hasConceptScore W4211054795C126322002 @default.
• W4211054795 hasConceptScore W4211054795C141071460 @default.
• W4211054795 hasConceptScore W4211054795C164705383 @default.
• W4211054795 hasConceptScore W4211054795C2777546689 @default.
• W4211054795 hasConceptScore W4211054795C2777698277 @default.
• W4211054795 hasConceptScore W4211054795C2778213512 @default.
• W4211054795 hasConceptScore W4211054795C2778425758 @default.
• W4211054795 hasConceptScore W4211054795C2778583881 @default.
• W4211054795 hasConceptScore W4211054795C2780400711 @default.
• W4211054795 hasConceptScore W4211054795C45393284 @default.
• W4211054795 hasConceptScore W4211054795C500558357 @default.
• W4211054795 hasConceptScore W4211054795C71924100 @default.
• W4211054795 hasLocation W42110547951 @default.
• W4211054795 hasLocation W42110547952 @default.
• W4211054795 hasLocation W42110547953 @default.
• W4211054795 hasLocation W42110547954 @default.
• W4211054795 hasOpenAccess W4211054795 @default.
• W4211054795 hasPrimaryLocation W42110547951 @default.
• W4211054795 hasRelatedWork W193640619 @default.
• W4211054795 hasRelatedWork W2127687375 @default.
• W4211054795 hasRelatedWork W2145553842 @default.
• W4211054795 hasRelatedWork W2355614377 @default.
• W4211054795 hasRelatedWork W2375584960 @default.
• W4211054795 hasRelatedWork W2378890344 @default.
• W4211054795 hasRelatedWork W2782203991 @default.
• W4211054795 hasRelatedWork W3029377117 @default.
• W4211054795 hasRelatedWork W3029448752 @default.
• W4211054795 hasRelatedWork W4318064246 @default.
• W4211054795 hasVolume "8" @default.
• W4211054795 isParatext "false" @default.

• next